<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Genes &amp; Cells</journal-id><journal-title-group><journal-title xml:lang="en">Genes &amp; Cells</journal-title><trans-title-group xml:lang="ru"><trans-title>Гены и Клетки</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Genes and Cells</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-1829</issn><issn publication-format="electronic">2500-2562</issn><publisher><publisher-name xml:lang="en">Human Stem Cells Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">121911</article-id><article-id pub-id-type="doi">10.23868/202107006</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Features of cytokine production in tumor associated with metastasis and basal cell hyperplasia of bronchial epithelium in non-small cell lung cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Особенности продукции цитокинов в опухоли, связанных с метастазированием и наличием базальноклеточной гиперплазии бронхиального эпителия, при немелкоклеточном раке легкого</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pismenny</surname><given-names>D. S</given-names></name><name xml:lang="ru"><surname>Письменный</surname><given-names>Д. С</given-names></name></name-alternatives><email>pismenniy.dmitry@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Durova</surname><given-names>A. A</given-names></name><name xml:lang="ru"><surname>Дурова</surname><given-names>А. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Krahmal'</surname><given-names>N. V</given-names></name><name xml:lang="ru"><surname>Крахмаль</surname><given-names>Н. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Stepanov</surname><given-names>I. V</given-names></name><name xml:lang="ru"><surname>Степанов</surname><given-names>И. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rodionov</surname><given-names>E. O</given-names></name><name xml:lang="ru"><surname>Родионов</surname><given-names>Е. О</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Eryomin</surname><given-names>V. A</given-names></name><name xml:lang="ru"><surname>Ерёмин</surname><given-names>В. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Andryuhova</surname><given-names>E. S</given-names></name><name xml:lang="ru"><surname>Андрюхова</surname><given-names>Е. С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Savelieva</surname><given-names>O. E</given-names></name><name xml:lang="ru"><surname>Савельева</surname><given-names>О. Е</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zavyalova</surname><given-names>M. V</given-names></name><name xml:lang="ru"><surname>Завьялова</surname><given-names>М. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pankova</surname><given-names>O. V</given-names></name><name xml:lang="ru"><surname>Панкова</surname><given-names>О. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tashireva</surname><given-names>L. A</given-names></name><name xml:lang="ru"><surname>Таширева</surname><given-names>Л. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vtorushin</surname><given-names>S. V</given-names></name><name xml:lang="ru"><surname>Вторушин</surname><given-names>С. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Miller</surname><given-names>S. V</given-names></name><name xml:lang="ru"><surname>Миллер</surname><given-names>С. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tuzikov</surname><given-names>S. A</given-names></name><name xml:lang="ru"><surname>Тузиков</surname><given-names>С. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Perelmuter</surname><given-names>V. M</given-names></name><name xml:lang="ru"><surname>Перельмутер</surname><given-names>В. М</given-names></name></name-alternatives><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Cancer Research Institute, Tomsk National Research Medical Center of the RAS</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский институт онкологии Томского национального медицинского исследовательского центра РАН</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Siberian State Medical University</institution></aff><aff><institution xml:lang="ru">Сибирский государственный медицинский университет</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="ru">Сибирский государственный медицинский университет</institution></aff><aff><institution xml:lang="en">Cancer Research Institute, Tomsk National Research Medical Center of the RAS</institution></aff></aff-alternatives><aff id="aff4"><institution>Научно-исследовательский институт онкологии Томского национального медицинского исследовательского центра РАН</institution></aff><pub-date date-type="pub" iso-8601-date="2021-06-15" publication-format="electronic"><day>15</day><month>06</month><year>2021</year></pub-date><volume>16</volume><issue>2</issue><issue-title xml:lang="en">VOL 16, NO2 (2021)</issue-title><issue-title xml:lang="ru">ТОМ 16, №2 (2021)</issue-title><fpage>54</fpage><lpage>60</lpage><history><date date-type="received" iso-8601-date="2023-01-16"><day>16</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Эко-Вектор</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2024-06-15"/></permissions><self-uri xlink:href="https://genescells.ru/2313-1829/article/view/121911">https://genescells.ru/2313-1829/article/view/121911</self-uri><abstract xml:lang="en"><p>The emergence and progression of a tumor (relapses, metastasis) is largely due to the presence and nature of inflammatory processes. It is promising to clarify the pathogenetic role and prognostic value of cytokines involved in the inflammation. The basal cell hyperplasia in the bronchial epithelium adjacent to the tumor may be associated with inflammation in the tumor microenvironment. Objective: to study the production of inflammatory cytokines in the tumor, taking into account basal cell hyperplasia in the bronchial epithelium adjacent to the tumor in the patients with nonsmall cell lung cancer. 35 patients with non-small cell lung cancer (T1-3N0-2M0) were included in the study. Neoadjuvant chemotherapy was administered in 17 cases. The production of TGF-β, TNF-α, SDF-1, VEGFA was determined by immunohistochemistry in tumor cells and alveolar macrophages. Basal cell hyperplasia in the bronchi adjacent to the tumor was morphologically diagnosed. The absence of SDF-1 in the nuclei of tumor cells was associated with the hematogenous metastases in patients with BCH of the bronchi adjacent to the tumor. Basal cell hyperplasia is correlated with an increased TGF-β production in alveolar macrophages and a decreased of SDF-1 in the cytoplasm of tumor cells. The frequency of case TNF-α in alveolar macrophages is reduced in patients with hematogenous metastases who received neoadjuvant chemotherapy. Cytokine production in the tumor cells and leukocytes was associated with the hematogenous metastases, taking into account the basal cell hyperplasia, which is associated with the pro-inflammatory cytokines in the tumor. The effects of neoadjuvant chemotherapy differ depending hematogenous metastasis.</p></abstract><trans-abstract xml:lang="ru"><p>Возникновение и прогрессия опухоли (рецидивирование, метастазирование), во многом, связаны с наличием и характером воспалительных процессов. Перспективным является уточнение патогенетической роли и прогностической ценности продукции цитокинов, участвующих в воспалении. Развитие базальноклеточной гиперплазии эпителия в смежных с опухолью бронхах может быть ассоциировано с воспалением в микроокружении опухоли. Цель исследования: изучить продукцию цитокинов в опухоли при немелкоклеточном раке легкого, ассоциированных с воспалением и гематогенным метастазированием, с учетом морфологических изменений эпителия в бронхах, смежных с опухолью. Группу исследования составили 35 пациентов с немелкоклеточным раком легкого (T1-3N0-2M0). В 17 случаях проводили неоадъювантную химиотерапию. Для изучения продукции цитокинов TGF-β, TNF-α, SDF-1, VEGFA в клетках опухоли и альвеолярных макрофагах применяли иммуногистохимический метод анализа. Базальноклеточная гиперплазия морфологически была диагностирована в мелких бронхах, расположенных на удалении 3-4 см от первичной опухоли. Отсутствие синтеза SDF-1 в ядрах опухолевых клеток было ассоциировано с развитием гематогенных метастазов при наличии базальноклеточной гиперплазии в смежных с опухолью бронхах. Развитие базальноклеточной гиперплазии коррелировало с увеличением случаев обнаружения продукции TGF-β альвеолярными макрофагами и уменьшением случаев выявления SDF-1 в цитоплазме клеток опухоли. У пациентов с гематогенными метастазами, получавших неоадъювантную химиотерапию, была снижена частота случаев обнаружения TNF-α в альвеолярных макрофагах. На основании полученных данных можно заключить, что при возникновении базальноклеточной гиперплазии продукция цитокинов клетками опухоли и лейкоцитами была ассоциирована с появлением гематогенных метастазов. Базальноклеточная гиперплазия была также связана с наличием или отсутствием провоспалительных цитокинов в опухоли. Эффекты неоадъювантной химиотерапии проявлялись у пациентов с гематогенными метастазами с меньшей частотой случаев выявления TNF-a в альвеолярных макрофагах.</p></trans-abstract><kwd-group xml:lang="en"><kwd>non-small cell lung cancer</kwd><kwd>hematogenous metastasis</kwd><kwd>basal cell hyperplasia</kwd><kwd>cytokines</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>немелкоклеточный рак легкого</kwd><kwd>гематогенное метастазирование</kwd><kwd>базальноклеточная гиперплазия</kwd><kwd>цитокины</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Москва: МНИОИ им. П.А. Герцена -Travis W.D., Brambilla E., Burke A.P. et al. World Health Organization classification of tumors of the lung, pleura, thymus, and heart. 4th Edition, Volume 7. Lyon: WHO press; 2015.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Onc. 2005; 23(5): 1011-27.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Eser P.O., Janne P.A. TGFp pathway inhibition in the treatment of non-small cell lung cancer. Pharmac. Ther. 2018; 184: 112-30.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Li J., Shen C., Wang X. et al. Prognostic value of TGF-p in lung cancer: systematic review and meta-analysis. BMC Cancer 2019; 19: 691.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Li J., Song Y., Yu B. et al. TNFAIP2 Promotes Non-Small Cell Lung Cancer Cells and Targeted by miR-145-5p. DNA and Cell Biology 2020; 39(7): 1256-63.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Zhu J., Xin Y., Liu X. et al. Nimotuzumab enhances the sensitivity of non-small cell lung cancer cells to tumor necrosis factor-α by inhibiting the nuclear factor-α signaling pathway. Exp. Ther. Med. 2018; 15(4): 3345-51.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Zhu T., Bao X., Chen M. et al. Mechanisms and future of non-small cell lung cancer metastasis. Front. Oncol. 2020; 10: 585284.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Zeng Y., Wang X., Yin B. et al. Role of the stromal cell derived factor-1/CXC chemokine receptor 4 axis in the invasion and metastasis of lung cancer and mechanism. J. Thor. Dis. 2017; 9(12): 4947-59.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Belperio J.A., Phillips R.J., Burdick M.D. et al. The SDF-1/CXCL 12/ CXCR4 biological axis in non-small cell lung cancer metastases. Chest 2004; 125(5): 156S.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kowanetz M., Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res.2006; 12(17): 5018-22.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Karaman S., Leppanen V.M., Alitalo K. Vascular endothelial growth factor signaling in development and disease. Development 2018; 145(14): dev151019.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Seto T., Higashiyama M., Funai H. et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I. non-small-cell lung cancer. Lung Cancer 2006; 53(1): 91-6.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Lantuejoul S., Salameire D., Salon C. et al. Pulmonary preneoplasia- sequential molecular carcinogenetic events. Histopathology 2009; 54(1): 43-54.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kadara H., Wistuba I.I. Molecular biology of lung preneoplasia. Lung Cancer 2014; 6: 110-28.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Kerr K.M. Pulmonary preinvasive neoplasia. J. Clin. Path. 2001; 54(4): 257-71.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Wang G.F., Lai M.D., Yang R.R. et al. Histological types and significance of bronchial epithelial dysplasia. Modern Path. 2006; 19(3): 429-37.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Breuer R.H., Pasic A., Smit E.F. et al. The natural course of preneoplastic lesions in bronchial epithelium. Clin. Cancer Res. 2005; 11(2): 537-43.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Greenberg A.K., Yee H., Rom W.N. Preneoplastic lesions of the lung. Resp. Res. 2002; 3(1): 1-10.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Pankova O.V., Denisov E.V., Ponomaryova A.A. et al. Recurrence of squamous cell lung carcinoma is associated with the co-presence of reactive lesions in tumor-adjacent bronchial epithelium. Tumor Biology 2016; 37(3): 3599-607.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Denisov E.V., Schegoleva A.A., Gerashchenko T.S. et al. Gene expression profiling revealed 2 types of bronchial basal cell hyperplasia and squamous metaplasia with different progression potentials. Appl. Immunohist. Mol. Morph. 2020; 28(6): 477-83.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Petrov S.V., Raikhlin N.T. Manual on immunohistochemical diagnostics of human tumors. In: Petrov S.V., Raikhlin N.T., editors. Molecular genetic and immunohistochemical characteristics of lung cancer. 3th, completely revised edition. Kazan: Tatmedia; 2004. p. 456-61.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Pankova O.V., Rodionov E.O., Miller S.V. et al. Neoadjuvant chemotherapy combined with intraoperative radiotherapy is effective to prevent recurrence in high-risk non-small cell lung cancer (NSCLC) patients. Transl. Lung Cancer Res. 2020; 9(4): 988.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Tashireva L.A., Perelmuter V.M., Denisov E.V. et al. Types of immune-inflammatory responses as a reflection of cell-cell interactions under conditions of tissue regeneration and tumor growth. Biochemistry (Moscow) 2017; 82(5): 732-48.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Kaplan R.N., Psaila B., Lyden D. Niche-to-niche migration of bone-marrow-derived cells. Trends Mol. Med. 2007; 13(2): 72-81.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Voermans C., Anthony E.C., Mul E. et al. SDF-1-induced actin polymerization and migration in human hematopoietic progenitor cells. Exp. Hematol. 2001; 29(12): 1456-64.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Chen H.W., Du C.W., Wei X.L. et al. Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer. Curr. Mol. Med. 2013; 13(3): 410-6.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Liu F., Lang R., Wei J. et al. Increased expression of SDF-1/ CXCR4 is associated with lymph node metastasis of invasive micropapillary carcinoma of the breast. Histopathol. 2009; 54(6): 741-50.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Osman N.M., Osman W.M. SDF-1 and MMP2 cross talk in cancer cells and tumor microenvironment in non-small cell lung cancer. Egypt. J. Chest Dis. and Tubercul.2016; 65(2): 517-25.</mixed-citation></ref></ref-list></back></article>
